母亲使用倍他司汀后的妊娠结局：病例系列。
Pregnancy outcomes after maternal betahistine exposure: A case series.
机构信息
Izmir Katip Celebi University Faculty of Pharmacy, Department of Pharmacology Izmir, Turkey.
Terafar - Izmir Katip Celebi University Teratology Information, Training and Research Center, Izmir, Turkey; Izmir Katip Celebi University School of Medicine, Department of Pharmacology Izmir, Turkey.
出版信息
Reprod Toxicol. 2018 Aug;79:79-83. doi: 10.1016/j.reprotox.2018.06.004. Epub 2018 Jun 13.
OBJECTIVE
To investigate the pregnancy outcomes of women who were exposed to betahistine during their pregnancies.
METHODS
We identified and evaluated the outcomes of 27 pregnant women who were referred to Terafar (Teratology Information Service, Izmir, Turkey) for a teratological risk assessment.
RESULTS
Of 24 pregnancies with known outcomes, 21 resulted in live births (including two pairs of twins) whereas two ended with miscarriage and three with elective terminations. Among the 20 live births for whom the malformation details were available, there were 17 normal outcomes, one major and two minor congenital malformations.
CONCLUSIONS
Despite a number of limitations, this case series may be of value regarding counseling pregnant women with inadvertent betahistine exposure. Further epidemiological studies with larger sample sizes and control groups are necessary to draw more definite conclusions.
目的
研究孕期接触培他司汀的女性的妊娠结局。
方法
我们识别并评估了 27 名因致畸风险评估而转至 Terafar（土耳其伊兹密尔畸形信息服务处）的孕妇的结局。
结果
24 例已知结局的妊娠中，21 例活产（包括两对双胞胎），2 例流产，3 例选择性终止妊娠。在 20 例畸形详情已知的活产儿中，17 例结果正常，1 例存在重大畸形，2 例存在轻微畸形。
结论
尽管存在诸多局限性，但本病例系列可能为意外接触培他司汀的孕妇提供有价值的咨询信息。需要进一步开展具有更大样本量和对照组的流行病学研究，以得出更明确的结论。
Zotero 插件